Trials / Unknown
UnknownNCT01995721
4-valent HPV Vaccine to Treat Recurrent Respiratory Papillomatosis in Children
Phase III, Single-center Clinical Trial to Evaluate the 4-valent HPV Vaccine for the Treatment and Prevention of Recurrent Respiratory Papillomatosis in Children
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- National Institute of Child Health, Hungary · Academic / Other
- Sex
- All
- Age
- 1 Year – 17 Years
- Healthy volunteers
- Not accepted
Summary
Recurrent respiratory papillomatosis in children caused by HPV 6,11 can be a life threatening condition resulting in surgical interventions. The maturing and disintegrating papillomas are the sources for the subsequent HPV relapses and immunization might slow down or even prevent this ongoing process. After an initial immunological and ear-nose-throat (ENT) assessment children with at least 3 relapses in their patient history will be vaccinated with 4-valent HPV vaccine according to the following schedule: 0., 2., 6. months. It will be followed by an immunological and 3 ENT examinations to assess response to vaccination.
Detailed description
1. Enrollment * ear-nose-throat (ENT) examination + oesophagoscopy * immunological assessment * assessment of selected humoral (antibodies) and * cellular immune response parameters(INF gamma and granzyme B testing) * in vitro and in vivo stimulation of PMBCs with the HPV-4 vaccine 2. Immunization with 4-valent HPV vaccine at 0,2,6 months 3. Follow up * 1 month after 3rd vaccine dose - immunological assessment (same tests as in the enrollment phase) * 6, 12 and 18 months after the 3rd vaccine dose - ENT + oesophagoscopy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | 4-valent HPV vaccine | Vaccination with 4-valent HPV vaccine in months 0., 2., 6. |
Timeline
- Start date
- 2014-02-01
- Primary completion
- 2017-02-01
- Completion
- 2017-02-01
- First posted
- 2013-11-27
- Last updated
- 2013-11-27
Locations
1 site across 1 country: Hungary
Source: ClinicalTrials.gov record NCT01995721. Inclusion in this directory is not an endorsement.